Analysts Offer Predictions for JSPR FY2026 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($3.96) per share for the year. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share.

JSPR has been the topic of a number of other research reports. Oppenheimer dropped their price objective on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. UBS Group reduced their price target on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has an average rating of "Buy" and an average target price of $62.22.

Jasper Therapeutics Stock Down 2.9%

NASDAQ:JSPR traded down $0.17 on Tuesday, hitting $5.77. The stock had a trading volume of 248,826 shares, compared to its average volume of 299,768. The stock has a market cap of $86.68 million, a price-to-earnings ratio of -1.22 and a beta of 2.72. The business's 50-day simple moving average is $4.71 and its two-hundred day simple moving average is $8.96. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Institutional Trading of Jasper Therapeutics

Several institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock worth $579,000 after acquiring an additional 3,310 shares in the last quarter. Deutsche Bank AG lifted its position in Jasper Therapeutics by 30.0% in the fourth quarter. Deutsche Bank AG now owns 170,695 shares of the company's stock worth $3,649,000 after buying an additional 39,436 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock valued at $159,000 after purchasing an additional 3,828 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in Jasper Therapeutics in the 4th quarter worth about $428,000. Finally, Soleus Capital Management L.P. lifted its stake in Jasper Therapeutics by 11.2% in the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock worth $31,951,000 after purchasing an additional 150,755 shares during the last quarter. Hedge funds and other institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.